{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:08:01Z","timestamp":1793340481948,"version":"4.5.0"},"reference-count":69,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-041269"],"award-info":[{"award-number":["INV-041269"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R00MH121166"],"award-info":[{"award-number":["R00MH121166"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Maximising the impact of new and forthcoming long-acting injectable HIV pre-exposure prophylaxis (PrEP) products will require novel delivery approaches that widen accessibility and prioritise clients\u2019 needs and preferences. To understand the potential barriers and facilitators to delivering injectable PrEP via private pharmacies in Kenya, we conducted qualitative formative research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From July to September 2023, we interviewed pharmacy providers, pharmacy clients and other key stakeholders of HIV service delivery in Central and Western Kenya. Our purposive sample included some providers and clients with prior experience delivering or obtaining oral PrEP at a pharmacy as part of a pilot study and some without such experience. We analysed verbatim transcripts thematically using a combination of inductive and deductive approaches, the latter informed by the Consolidated Framework for Implementation Research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We interviewed 25 pharmacy clients, 16 pharmacy providers and nine key stakeholders. Each group was ~50% female, and median age among clients was 25 (IQR 23\u201329). Overall, participants supported the idea of pharmacy-based injectable PrEP delivery. Anticipated facilitators included perceived benefits of injectable over oral PrEP; characteristics of pharmacies (eg, long operating hours) that could fulfil clients\u2019 need for accessible, fast and private injectable PrEP services; and existing skillsets of pharmacy providers, especially those already trained on injectable contraception. Anticipated barriers included gaps in enabling policy; pharmacies\u2019 lack of integration with the public health sector, such as its health information system; low client knowledge of and\/or ability to pay for injectable PrEP and pharmacy staffing and compensation structures that could disincentivise providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants in this study expressed cautious optimism that private pharmacies could be an effective delivery channel for injectable PrEP in Kenya. If private pharmacies facilitate access to and use of injectable PrEP, they could play a pivotal role in ending HIV as a public health threat.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2025-019210","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:00:14Z","timestamp":1769612414000},"page":"e019210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Implementing long-acting injectable HIV pre-exposure prophylaxis services at private pharmacies in Kenya: client, pharmacy provider and key stakeholder perspectives on potential challenges and opportunities"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7569-3241","authenticated-orcid":false,"given":"Stephanie D","family":"Roche","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kamolloh","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Thuo","sequence":"additional","affiliation":[{"name":"Partners in Health and Research Development, Thika, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Opiyo","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallery","family":"Ogello","sequence":"additional","affiliation":[{"name":"Partners in Health and Research Development, Thika, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Odira","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmah","family":"Owidi","sequence":"additional","affiliation":[{"name":"Partners in Health and Research Development, Thika, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perez","family":"Ochwal","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Hewa","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Adiema","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Mogaka","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor O","family":"Omollo","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C","family":"Malen","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Harkey","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenell","family":"Stewart","sequence":"additional","affiliation":[{"name":"Hennepin Healthcare, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ngure","sequence":"additional","affiliation":[{"name":"Department of Global Health, University of Washington, Seattle, Washington, USA"},{"name":"School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina F","family":"Ortblad","sequence":"additional","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Bukusi","sequence":"additional","affiliation":[{"name":"Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya"},{"name":"Department of Global Health, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"2026012807000821000_11.1.e019210.1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2022","journal-title":"Lancet HIV"},{"key":"2026012807000821000_11.1.e019210.2","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00365-4","article-title":"Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study","volume":"10","author":"Smith","year":"2023","journal-title":"Lancet HIV"},{"key":"2026012807000821000_11.1.e019210.3","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3018(23)00026-7","article-title":"Defining principles for a choice-based approach to HIV prevention","volume":"10","author":"Williams","year":"2023","journal-title":"Lancet HIV"},{"key":"2026012807000821000_11.1.e019210.4","unstructured":"AVAC . Country planning for product introduction matrix. 2024. Available: https:\/\/app.powerbi.com\/view?r=eyJrIjoiMzc4ZWQwZGMtZTk4Yi00MTY4LWJiNGItNjRkNGRhNTZiMzIzIiwidCI6ImFmNjQ0ZDZjLWFlYmUtNDRkMi1hNDc2LTczOTdlZmJhMWEzZiIsImMiOjN9"},{"key":"2026012807000821000_11.1.e019210.5","unstructured":"World Health Organization . FDA approval of injectable lenacapavir marks progress for HIV prevention [press release]. Geneva World Health Organization; 2025. Available: https:\/\/www.who.int\/news\/item\/19-06-2025-fda-approval-of-injectable-lenacapavir-marks-progress-for-hiv-prevention [accessed 20 Aug 2025]"},{"key":"2026012807000821000_11.1.e019210.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407001"},{"key":"2026012807000821000_11.1.e019210.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411858"},{"key":"2026012807000821000_11.1.e019210.8","unstructured":"UNAIDS . UNAIDS data 2023. Geneva UNAIDS; 2023."},{"key":"2026012807000821000_11.1.e019210.9","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26103","article-title":"Preparing for long-acting PrEP delivery: building on lessons from oral PrEP","volume":"26 Suppl 2","author":"Celum","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2026012807000821000_11.1.e019210.10","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26095","article-title":"The importance of the \u201chow\u201d: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment","volume":"26 Suppl 2","author":"Grimsrud","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2026012807000821000_11.1.e019210.11","unstructured":"World Health Organization . Guidelines on long-acting injectable cabotegravir for HIV prevention. Geneva World Health Organization; 2022."},{"key":"2026012807000821000_11.1.e019210.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-11335-1","article-title":"Facilitators and barriers to HIV pre-exposure prophylaxis (PrEP) uptake through a community-based intervention strategy among adolescent girls and young women in Seme Sub-County, Kisumu, Kenya","volume":"21","author":"Jackson-Gibson","year":"2021","journal-title":"BMC Public Health"},{"key":"2026012807000821000_11.1.e019210.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258542","article-title":"Adolescent girls and young women\u2019s PrEP-user journey during an implementation science study in South Africa and Kenya","volume":"16","author":"Rousseau","year":"2021","journal-title":"PLoS ONE"},{"key":"2026012807000821000_11.1.e019210.14","doi-asserted-by":"crossref","DOI":"10.1186\/s43058-024-00637-1","article-title":"The pathway to delivering injectable CAB for HIV prevention: strategies from global PrEP leaders leveraging an adapted version of the Intervention Scalability Assessment Tool (ISAT)","volume":"5","author":"Violette","year":"2024","journal-title":"Implement Sci Commun"},{"key":"2026012807000821000_11.1.e019210.15","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3018(24)00274-1","article-title":"Injectable PrEP comes to southern Africa","volume":"11","author":"Pebody","year":"2024","journal-title":"Lancet HIV"},{"key":"2026012807000821000_11.1.e019210.16","doi-asserted-by":"crossref","unstructured":"The Lancet HIV . PrEParing to curb the HIV epidemic in Zambia. Lancet HIV 2024;11. doi:10.1016\/S2352-3018(24)00064-X","DOI":"10.1016\/S2352-3018(24)00064-X"},{"key":"2026012807000821000_11.1.e019210.17","unstructured":"Hoege D , ed. PathToScale for injectable PrEP in Malawi: formative insights from providers and clients and managing demand for new products. In: The 5th HIV Research for Prevention conference (HIVR4P); Lima, Peru, 2024"},{"key":"2026012807000821000_11.1.e019210.18","unstructured":"Ncube G . Early experiences with CAB PrEP in Zimbabwe [Webinar]. Global PrEP Learning Network; 2024."},{"key":"2026012807000821000_11.1.e019210.19","unstructured":"Patel R , Golden M , Keita R , et al . Feasibility of long-acting injectable cabotegravir PrEP initiation and administration by community health workers and early aspects of the PrEP injection care continuum in a primary care center in Washington D.C. The 12th International AIDS Conference on HIV Science (IAS); 2023, Brisbane, Australia."},{"key":"2026012807000821000_11.1.e019210.20","unstructured":"Pharmacy K-R . One-step PrEP: long-acting injectable for PrEP. 2024. Available: https:\/\/one-step-prep.com\/how-it-works\/long-acting-injectable-for-prep"},{"key":"2026012807000821000_11.1.e019210.21","unstructured":"Kenya Ministry of Health, National AIDS Control Council . Kenya AIDS strategic framework II 2020\/21 - 2024\/2025. 2021."},{"key":"2026012807000821000_11.1.e019210.22","unstructured":"MOSAIC . CAB PrEP introduction situation analysis in Kenya. 2023."},{"key":"2026012807000821000_11.1.e019210.23","unstructured":"National A , Program SC . Private sector engagement framework for delivery of HIV services in Kenya 2023-2028. Nairobi NASCOP; 2023."},{"key":"2026012807000821000_11.1.e019210.24","doi-asserted-by":"crossref","DOI":"10.1007\/s11904-024-00710-3","article-title":"Feasibility and Impact of Community Pharmacy and Novel Pick-up Points for Antiretroviral Therapy Pre-exposure Prophylaxis Initiation and Continuation in Low and Middle-income Countries","volume":"22","author":"Lalla-Edward","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026012807000821000_11.1.e019210.25","unstructured":"Kenya Pharmacy and Poisons Board . PPB registers Nairobi: PPB. 2024. Available: https:\/\/practice.pharmacyboardkenya.org\/LicenseStatus"},{"key":"2026012807000821000_11.1.e019210.26","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S348816"},{"key":"2026012807000821000_11.1.e019210.27","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v70i6.1713"},{"key":"2026012807000821000_11.1.e019210.28","unstructured":"Kenya National Bureau of Statistics, ICF . Kenya demographic and health survey 2022: Volume 1. Nairobi, Kenya, 2023. Available: https:\/\/dhsprogram.com\/publications\/publication-FR380-DHS-Final-Reports.cfm"},{"key":"2026012807000821000_11.1.e019210.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258578","article-title":"Prevalence and correlates of pregnancy self-testing among pregnant women attending antenatal care in western Kenya","volume":"16","author":"Nganga","year":"2021","journal-title":"PLoS One"},{"key":"2026012807000821000_11.1.e019210.30","unstructured":"SHOPS Plus, USAID . Assessment of the pregnancy test market in Kenya. Washington, D.C USAID; 2017. Available: https:\/\/www.rhsupplies.org\/uploads\/tx_rhscpublications\/Assessment_of_the_Pregnancy_Test_Market_in_Kenya.pdf"},{"key":"2026012807000821000_11.1.e019210.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001776","article-title":"Characterising the HIV self-testing market in Kenya: Awareness and usage, barriers and motivators to uptake, and propensity to pay","volume":"3","author":"West","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"2026012807000821000_11.1.e019210.32","unstructured":"Kidake KF . Prevalence and factors associated with the use of sexual enhancers and erectile dysfunctoin medications among male undergraduates aged 18-35yrs at Jomo Kenyatta University of Agriculture and Technology, Kenya. Nairobi, Kenya Jomo Kenyatta University of Agriculture and Technology; 2023. Available: http:\/\/ir.jkuat.ac.ke\/bitstream\/handle\/123456789\/6114\/Kayose%27s%2C%2C%20Flaviah.%20MSC%20public%20Health%2C%202023%20%282%29.pdf?sequence=1&isAllowed=y"},{"key":"2026012807000821000_11.1.e019210.33","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26131","article-title":"Stand\u2010alone model for delivery of oral HIV pre\u2010exposure prophylaxis in Kenya: a single\u2010arm, prospective pilot evaluation","volume":"26","author":"Ortblad","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2026012807000821000_11.1.e019210.34","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26467","article-title":"A modified pharmacy provider-led delivery model of oral HIV pre- and post-exposure prophylaxis in Kenya: a pilot study extension","volume":"28 Suppl 1","author":"Roche","year":"2025","journal-title":"J Int AIDS Soc"},{"key":"2026012807000821000_11.1.e019210.35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/QAD.0000000000003447","article-title":"Nurse-facilitated preexposure prophylaxis delivery for adolescent girls and young women seeking contraception at retail pharmacies in Kisumu, Kenya","volume":"37","author":"Pintye","year":"2023","journal-title":"AIDS"},{"key":"2026012807000821000_11.1.e019210.36","unstructured":"Vera M , Pintye J , Odoyo J , eds. Experiences with pharmacy-based PrEP delivery among adolescent girls and young women seeking contraception in Kisumu, Kenya: a qualitative analysis (Abstract 1050). Adherence 2022. Washington, DC, 2022."},{"key":"2026012807000821000_11.1.e019210.37","unstructured":"Pharmacy K , Board P . All registered medicines 2025. Available: https:\/\/products.pharmacyboardkenya.org\/ppb_admin\/pages\/public_view_retention_products.php [Accessed 20 Aug 2025]."},{"key":"2026012807000821000_11.1.e019210.38","unstructured":"AVAC . What with injectable LEN for PrEP [press release]. 2025. Available: https:\/\/avac.org\/wp-content\/uploads\/2025\/07\/Now-What-With-Injectable-LEN-for-PrEP.pdf [Accessed 10 Aug 2025]."},{"key":"2026012807000821000_11.1.e019210.39","unstructured":"Otieno TE . Kenya among countries set to roll out HIV preventive drug Lenacapavir. Citizen Digital; 2025. Available: https:\/\/www.citizen.digital\/news\/kenya-among-countries-set-to-roll-out-hiv-preventive-drug-lenacapavir-n366306 [Accessed 20 Aug 2025]."},{"key":"2026012807000821000_11.1.e019210.40","unstructured":"National Syndemic Diseases Control Council . HIV estimates. 2024. Available: https:\/\/analytics.nsdcc.go.ke\/estimates\/#!\/kenya\/subcounty"},{"key":"2026012807000821000_11.1.e019210.41","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"2026012807000821000_11.1.e019210.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-017-0550-7","article-title":"Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation","volume":"12","author":"Keith","year":"2017","journal-title":"Implement Sci"},{"key":"2026012807000821000_11.1.e019210.43","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1007\/s10461-021-03229-5","article-title":"Acceptability and Feasibility of Pharmacy-Based Delivery of Pre-Exposure Prophylaxis in Kenya: A Qualitative Study of Client and Provider Perspectives","volume":"25","author":"Roche","year":"2021","journal-title":"AIDS Behav"},{"key":"2026012807000821000_11.1.e019210.44","doi-asserted-by":"crossref","DOI":"10.3389\/frph.2023.1023568","article-title":"Barriers to and strategies for early implementation of pharmacy-delivered HIV PrEP services in Kenya: An analysis of routine data","volume":"5","author":"Nakambale","year":"2023","journal-title":"Front Reprod Health"},{"key":"2026012807000821000_11.1.e019210.45","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-42"},{"key":"2026012807000821000_11.1.e019210.46","unstructured":"Hamilton A . Qualitative methods in rapid turn-around health services research. 2013."},{"key":"2026012807000821000_11.1.e019210.47","unstructured":"Salda\u00f1a J . The coding manual for qualitative researchers. 3rd edn. SAGE Publications Ltd, 2015."},{"key":"2026012807000821000_11.1.e019210.48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309811","article-title":"Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084","volume":"19","author":"Tolley","year":"2024","journal-title":"PLoS One"},{"key":"2026012807000821000_11.1.e019210.49","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26252","article-title":"HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study","volume":"27","author":"Psaros","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026012807000821000_11.1.e019210.50","unstructured":"Kakande E , Balzer L , Kambami J , eds. Knowledge, awareness, feasibility, and acceptability of long-acting cabotegravir for HIV prevention: results from the search dynamic choice HIV prevention trial (Abstract OAE1203). In: The 25th International AIDS Conference; Munich, Germany, 2024"},{"key":"2026012807000821000_11.1.e019210.51","unstructured":"AVAC, BioPIC . Coordinating implementation science for CAB for PrEP: Early Insights from EBONI and PILLAR [webinar]. 2024."},{"key":"2026012807000821000_11.1.e019210.52","unstructured":"Chisenga T . Early experiences with CAB PrEP in Zambia [Presentation within webinar titled \"Leading the way: Early learnings from CAB PrEP introduction in Zambia and Zimbabwe\"]. Global PrEP Learning Network; 2024."},{"key":"2026012807000821000_11.1.e019210.53","unstructured":"Saya M . 30 arrested, 100 unlicensed chemists shut in Rift Valley. Star; 2024."},{"key":"2026012807000821000_11.1.e019210.54","unstructured":"Mwale A , Njoki-Kna M . PPB steps up efforts to fight illegal pharmaceutical trade. Kenya Government Advertising Agency; 2024."},{"key":"2026012807000821000_11.1.e019210.55","unstructured":"MOSAIC . Provider support of PrEP use among adolescent girls & young women. 2023."},{"key":"2026012807000821000_11.1.e019210.56","unstructured":"Tembo A . Utilizing community pharmacies to initiate high-risk young women and men on oral pre-exposure prophylaxis (PrEP) in South Africa [symposium presentation]. The 25th International AIDS Conference; Munich, Germany, 2024"},{"key":"2026012807000821000_11.1.e019210.57","unstructured":"Kenya National Innovation Agency. 2021. Available: https:\/\/www.innovationagency.go.ke\/blog\/kenyan-app-helping-ppb-fight-counterfeit-pharmaceutical-products#:~:text=A%20Kenyan%20mobile%20based%20application,at%20the%20point%20of%20purchase [Accessed 12 Sep 2024]."},{"key":"2026012807000821000_11.1.e019210.58","unstructured":"RISE . Provider training toolkit on use of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). 2023."},{"key":"2026012807000821000_11.1.e019210.59","unstructured":"South African HIV Clinicians Society . Pharmacist Initiated Management of Antiretroviral Treatment (PIMART) online course. 2023. Available: https:\/\/sahivsoc.org\/Subheader\/Index\/pimart-online-course"},{"key":"2026012807000821000_11.1.e019210.60","unstructured":"American Pharmacists Association . Pharmacy-based HIV prevention services certificate training program. 2024. Available: https:\/\/www.pharmacist.com\/Education\/Certificate-Training-Programs\/Pharmacy-Based-HIV-Prevention-Services"},{"key":"2026012807000821000_11.1.e019210.61","unstructured":"ICAP . ICAP\u2019s pre-exposure prophylaxis (PrEP) package for providers: preparing for choice. New York Columbia Mailman School of Public Health; 2024. Available: https:\/\/icap.columbia.edu\/tools_resources\/icaps-pre-exposure-prophylaxis-prep-package-for-providers-preparing-for-choice"},{"key":"2026012807000821000_11.1.e019210.62","unstructured":"Cayalyst . CATALYST CAB PrEP job aid. 2024. Available: https:\/\/www.prepwatch.org\/wp-content\/uploads\/2024\/02\/CAB-PrEP-Job-Aid_providers_v2.0.pdf"},{"key":"2026012807000821000_11.1.e019210.63","unstructured":"John Snow Inc . Injectable HIV-prevention drug launches in Zambia. 2024. Available: https:\/\/www.jsi.com\/injectable-hiv-prevention-drug-launches-zambia"},{"key":"2026012807000821000_11.1.e019210.64","unstructured":"Landovitz R , Gao F , GFogel JM , eds. Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study [Abstract OAE0406LB]. In: The 25th International AIDS Conference; Munich, Germany, 2024"},{"key":"2026012807000821000_11.1.e019210.65","unstructured":"Patel RR , ed. Why is cabotegravir rollout so slow? [Symposium presentation \u201cPromise and Pitfalls of Biomedical Prevention: Beyond Phase III\u201d]. In: The 31st Conference on Retroviruses and Opportunistic Infections (CROI); Denver, USA, 2024"},{"key":"2026012807000821000_11.1.e019210.66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1186\/s12913-024-10995-0","article-title":"Low selection of HIV PrEP refills at private pharmacies among clients who initiated PrEP at public clinics: findings from a mixed-methods study in Kenya","volume":"24","author":"Ortblad","year":"2024","journal-title":"BMC Health Serv Res"},{"key":"2026012807000821000_11.1.e019210.67","unstructured":"Pharmacy-based PrEP Delivery in Kenya (NCT05842122). National Institutes of Health; 2023. Available: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05842122"},{"key":"2026012807000821000_11.1.e019210.68","doi-asserted-by":"crossref","DOI":"10.1177\/23259582231215882","article-title":"\"Pharmacies are Everywhere, and You can get it at any Time\": Experiences With Pharmacy-Based PrEP Delivery Among Adolescent Girls and Young Women in Kisumu, Kenya","volume":"22","author":"Vera","year":"2023","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2026012807000821000_11.1.e019210.69","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-024-08206-6","article-title":"Enhancing HIV pre-exposure prophylaxis outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform: protocol for a cluster-randomized controlled trial","volume":"25","author":"Lagat","year":"2024","journal-title":"Trials"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2025-019210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T15:00:27Z","timestamp":1769612427000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2025-019210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,28]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjgh-2025-019210"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2025-019210","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}